APO Research
Talk to an analyst

APO RESEARCH · REPORT

Homozygous Familial Hypercholesterolemia Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Research

Homozygous Familial Hypercholesterolemia Treatment Industry Research Report 2026

22 December 2025121 pages

Choose your research edition.

Industry ResearchHomozygous Familial Hypercholesterolemia Treatment Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Homozygous Familial Hypercholesterolemia Treatment Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Homozygous Familial Hypercholesterolemia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Homozygous Familial Hypercholesterolemia Treatment Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Homozygous Familial Hypercholesterolemia Treatment Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Homozygous Familial Hypercholesterolemia Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Homozygous Familial Hypercholesterolemia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Homozygous Familial Hypercholesterolemia Treatment is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Homozygous Familial Hypercholesterolemia Treatment is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Homozygous Familial Hypercholesterolemia Treatment include The Medicines Company, RegenxBio Inc, Regeneron Pharmaceuticals Inc, LipimetiX Development Inc, Gemphire Therapeutics Inc, Daewoong Co Ltd and CymaBay Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Homozygous Familial Hypercholesterolemia Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Homozygous Familial Hypercholesterolemia Treatment Market by Company

The Medicines Company

RegenxBio Inc

Regeneron Pharmaceuticals Inc

LipimetiX Development Inc

Gemphire Therapeutics Inc

Daewoong Co Ltd

CymaBay Therapeutics Inc

Homozygous Familial Hypercholesterolemia Treatment Segment by Type

Alirocumab

Evinacumab

AEM-2814

AEM-2802

Others

Homozygous Familial Hypercholesterolemia Treatment Segment by Application

Clinic

Hospital

Others

Homozygous Familial Hypercholesterolemia Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Homozygous Familial Hypercholesterolemia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Homozygous Familial Hypercholesterolemia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Homozygous Familial Hypercholesterolemia Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Homozygous Familial Hypercholesterolemia Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Homozygous Familial Hypercholesterolemia Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Homozygous Familial Hypercholesterolemia Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Homozygous Familial Hypercholesterolemia Treatment Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Homozygous Familial Hypercholesterolemia Treatment Sales (k units) of Manufacturers (2021-2026) Table 7. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Manufacturers (2021-2026) Table 8. Global Homozygous Familial Hypercholesterolemia Treatment Revenue of Manufacturers (2021-2026) Table 9. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Homozygous Familial Hypercholesterolemia Treatment Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Homozygous Familial Hypercholesterolemia Treatment Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Homozygous Familial Hypercholesterolemia Treatment, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Homozygous Familial Hypercholesterolemia Treatment, Product Type & Application Table 14. Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Homozygous Familial Hypercholesterolemia Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. The Medicines Company Company Information Table 19. The Medicines Company Business Overview Table 20. The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 22. The Medicines Company Recent Developments Table 23. RegenxBio Inc Company Information Table 24. RegenxBio Inc Business Overview Table 25. RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 27. RegenxBio Inc Recent Developments Table 28. Regeneron Pharmaceuticals Inc Company Information Table 29. Regeneron Pharmaceuticals Inc Business Overview Table 30. Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 32. Regeneron Pharmaceuticals Inc Recent Developments Table 33. LipimetiX Development Inc Company Information Table 34. LipimetiX Development Inc Business Overview Table 35. LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 37. LipimetiX Development Inc Recent Developments Table 38. Gemphire Therapeutics Inc Company Information Table 39. Gemphire Therapeutics Inc Business Overview Table 40. Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 42. Gemphire Therapeutics Inc Recent Developments Table 43. Daewoong Co Ltd Company Information Table 44. Daewoong Co Ltd Business Overview Table 45. Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 47. Daewoong Co Ltd Recent Developments Table 48. CymaBay Therapeutics Inc Company Information Table 49. CymaBay Therapeutics Inc Business Overview Table 50. CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 52. CymaBay Therapeutics Inc Recent Developments Table 53. Global Homozygous Familial Hypercholesterolemia Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 54. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2021-2026) & (k units) Table 55. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2021-2026) Table 56. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2027-2032) & (k units) Table 57. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2027-2032) Table 58. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region (2021-2026) Table 60. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region (2027-2032) Table 62. North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2026) & (k units) Table 64. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2027-2032) & (k units) Table 65. North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 66. North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2027-2032) & (US$ Million) Table 67. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2026) & (k units) Table 69. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2027-2032) & (k units) Table 70. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 71. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2027-2032) & (US$ Million) Table 72. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2026) & (k units) Table 74. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2027-2032) & (k units) Table 75. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 76. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2027-2032) & (US$ Million) Table 77. South America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. South America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2026) & (k units) Table 79. South America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2027-2032) & (k units) Table 80. South America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 81. South America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2027-2032) & (US$ Million) Table 82. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2026) & (k units) Table 84. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2027-2032) & (k units) Table 85. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 86. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2027-2032) & (US$ Million) Table 87. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2026) & (k units) Table 88. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2027-2032) & (k units) Table 89. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2021-2026) Table 90. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2027-2032) Table 91. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 92. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 93. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2021-2026) Table 94. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2027-2032) Table 95. Global Homozygous Familial Hypercholesterolemia Treatment Price by Type (2021-2026) & (US$/unit) Table 96. Global Homozygous Familial Hypercholesterolemia Treatment Price by Type (2027-2032) & (US$/unit) Table 97. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2026) & (k units) Table 98. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2027-2032) & (k units) Table 99. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2021-2026) Table 100. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2027-2032) Table 101. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 102. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 103. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2021-2026) Table 104. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2027-2032) Table 105. Global Homozygous Familial Hypercholesterolemia Treatment Price by Application (2021-2026) & (US$/unit) Table 106. Global Homozygous Familial Hypercholesterolemia Treatment Price by Application (2027-2032) & (US$/unit) Table 107. Key Raw Materials Table 108. Raw Materials Key Suppliers Table 109. Homozygous Familial Hypercholesterolemia Treatment Distributors List Table 110. Homozygous Familial Hypercholesterolemia Treatment Customers List Table 111. Homozygous Familial Hypercholesterolemia Treatment Industry Trends Table 112. Homozygous Familial Hypercholesterolemia Treatment Industry Drivers Table 113. Homozygous Familial Hypercholesterolemia Treatment Industry Restraints Table 114. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Homozygous Familial Hypercholesterolemia Treatment Product Image Figure 5. Global Homozygous Familial Hypercholesterolemia Treatment Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Homozygous Familial Hypercholesterolemia Treatment Market Size (2021-2032) & (US$ Million) Figure 7. Global Homozygous Familial Hypercholesterolemia Treatment Sales (2021-2032) & (k units) Figure 8. Global Homozygous Familial Hypercholesterolemia Treatment Average Price (US$/unit) & (2021-2032) Figure 9. Alirocumab Product Image Figure 10. Evinacumab Product Image Figure 11. AEM-2814 Product Image Figure 12. AEM-2802 Product Image Figure 13. Others Product Image Figure 14. Clinic Product Image Figure 15. Hospital Product Image Figure 16. Others Product Image Figure 17. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Homozygous Familial Hypercholesterolemia Treatment, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Homozygous Familial Hypercholesterolemia Treatment Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Homozygous Familial Hypercholesterolemia Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region in 2025 Figure 23. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region in 2025 Figure 24. North America Homozygous Familial Hypercholesterolemia Treatment Market Size by Country in 2025 Figure 25. North America Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2021-2032) Figure 26. North America Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country (2021-2032) Figure 27. United States Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Homozygous Familial Hypercholesterolemia Treatment Market Size by Country in 2025 Figure 31. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2021-2032) Figure 32. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country (2021-2032) Figure 33. Germany Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Size by Country in 2025 Figure 44. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country (2021-2032) Figure 46. China Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Homozygous Familial Hypercholesterolemia Treatment Market Size by Country in 2025 Figure 55. South America Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2021-2032) Figure 56. South America Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country (2021-2032) Figure 57. Brazil Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Market Size by Country in 2025 Figure 61. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country (2021-2032) Figure 63. Egypt Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2021-2032) Figure 69. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2021-2032) Figure 70. Global Homozygous Familial Hypercholesterolemia Treatment Price (US$/unit) by Type (2021-2032) Figure 71. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2021-2032) Figure 72. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2021-2032) Figure 73. Global Homozygous Familial Hypercholesterolemia Treatment Price (US$/unit) by Application (2021-2032) Figure 74. Homozygous Familial Hypercholesterolemia Treatment Value Chain Figure 75. Homozygous Familial Hypercholesterolemia Treatment Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Homozygous Familial Hypercholesterolemia Treatment Industry Opportunities and Challenges

Scope & coverage.

Types
  • Alirocumab
  • Evinacumab
  • AEM-2814
  • AEM-2802
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • The Medicines Company
  • RegenxBio Inc
  • Regeneron Pharmaceuticals Inc
  • LipimetiX Development Inc
  • Gemphire Therapeutics Inc
  • Daewoong Co Ltd
  • CymaBay Therapeutics Inc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size (2021-2032)
  4. 2.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales (2021-2032)
  5. 2.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Market Average Price (2021-2032)
  6. 2.3 Homozygous Familial Hypercholesterolemia Treatment by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Alirocumab
  9. 2.3.3 Evinacumab
  10. 2.3.4 AEM-2814
  11. 2.3.5 AEM-2802
  12. 2.3.6 Others
  13. 2.4 Homozygous Familial Hypercholesterolemia Treatment by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Clinic
  16. 2.4.3 Hospital
  17. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Homozygous Familial Hypercholesterolemia Treatment Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Homozygous Familial Hypercholesterolemia Treatment Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Homozygous Familial Hypercholesterolemia Treatment, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Homozygous Familial Hypercholesterolemia Treatment, Product Type & Application
  8. 3.8 Global Manufacturers of Homozygous Familial Hypercholesterolemia Treatment, Established Date
  9. 3.9 Global Homozygous Familial Hypercholesterolemia Treatment Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 The Medicines Company
  2. 4.1.1 The Medicines Company Company Information
  3. 4.1.2 The Medicines Company Business Overview
  4. 4.1.3 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  6. 4.1.5 The Medicines Company Recent Developments
  7. 4.2 RegenxBio Inc
  8. 4.2.1 RegenxBio Inc Company Information
  9. 4.2.2 RegenxBio Inc Business Overview
  10. 4.2.3 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  12. 4.2.5 RegenxBio Inc Recent Developments
  13. 4.3 Regeneron Pharmaceuticals Inc
  14. 4.3.1 Regeneron Pharmaceuticals Inc Company Information
  15. 4.3.2 Regeneron Pharmaceuticals Inc Business Overview
  16. 4.3.3 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  18. 4.3.5 Regeneron Pharmaceuticals Inc Recent Developments
  19. 4.4 LipimetiX Development Inc
  20. 4.4.1 LipimetiX Development Inc Company Information
  21. 4.4.2 LipimetiX Development Inc Business Overview
  22. 4.4.3 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  24. 4.4.5 LipimetiX Development Inc Recent Developments
  25. 4.5 Gemphire Therapeutics Inc
  26. 4.5.1 Gemphire Therapeutics Inc Company Information
  27. 4.5.2 Gemphire Therapeutics Inc Business Overview
  28. 4.5.3 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  30. 4.5.5 Gemphire Therapeutics Inc Recent Developments
  31. 4.6 Daewoong Co Ltd
  32. 4.6.1 Daewoong Co Ltd Company Information
  33. 4.6.2 Daewoong Co Ltd Business Overview
  34. 4.6.3 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  36. 4.6.5 Daewoong Co Ltd Recent Developments
  37. 4.7 CymaBay Therapeutics Inc
  38. 4.7.1 CymaBay Therapeutics Inc Company Information
  39. 4.7.2 CymaBay Therapeutics Inc Business Overview
  40. 4.7.3 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  42. 4.7.5 CymaBay Therapeutics Inc Recent Developments
5 Global Homozygous Familial Hypercholesterolemia Treatment Market Scenario by Region
  1. 5.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region: 2021-2032
  3. 5.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region: 2021-2026
  4. 5.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region: 2027-2032
  5. 5.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region: 2021-2032
  6. 5.3.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region: 2021-2026
  7. 5.3.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region: 2027-2032
  8. 5.4 North America Homozygous Familial Hypercholesterolemia Treatment Market Facts & Figures by Country
  9. 5.4.1 North America Homozygous Familial Hypercholesterolemia Treatment Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2032)
  11. 5.4.3 North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Homozygous Familial Hypercholesterolemia Treatment Market Facts & Figures by Country
  16. 5.5.1 Europe Homozygous Familial Hypercholesterolemia Treatment Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2032)
  18. 5.5.3 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Homozygous Familial Hypercholesterolemia Treatment Market Facts & Figures by Country
  41. 5.7.1 South America Homozygous Familial Hypercholesterolemia Treatment Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2032)
  43. 5.7.3 South America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2032)
  2. 6.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2021-2032)
  4. 6.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2032)
  5. 6.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Homozygous Familial Hypercholesterolemia Treatment Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2032)
  2. 7.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2021-2032)
  4. 7.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2032)
  5. 7.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Homozygous Familial Hypercholesterolemia Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Homozygous Familial Hypercholesterolemia Treatment Value Chain Analysis
  2. 8.1.1 Homozygous Familial Hypercholesterolemia Treatment Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Homozygous Familial Hypercholesterolemia Treatment Production Mode & Process
  5. 8.2 Homozygous Familial Hypercholesterolemia Treatment Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Homozygous Familial Hypercholesterolemia Treatment Distributors
  8. 8.2.3 Homozygous Familial Hypercholesterolemia Treatment Customers
9 Global Homozygous Familial Hypercholesterolemia Treatment Analyzing Market Dynamics
  1. 9.1 Homozygous Familial Hypercholesterolemia Treatment Industry Trends
  2. 9.2 Homozygous Familial Hypercholesterolemia Treatment Industry Drivers
  3. 9.3 Homozygous Familial Hypercholesterolemia Treatment Industry Opportunities and Challenges
  4. 9.4 Homozygous Familial Hypercholesterolemia Treatment Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst